Business, Commercial & Development Strategy
AT is a European pharmaceutical company. Its sales and much of its development effort are focused in the area of immunotherapy for allergy. Immunotherapy acts on the underlying immunological cause of the disease, and so offers a 'cure' not a treatment which merely addresses the symptoms of the disease. As a result, the right immunotherapeutic products should have great commercial potential.
AT's strategies are therefore :
- Continue to build our European commercial infrastructure
- Continue developing improved allergy vaccines with novel adjuvants, improved dosing characteristics and hence patient compliance and new delivery formulations generating a patent protected, registered product
- Broaden the portfolio through the in-licensing and co-development of selected products
- Identify strong commercial partners for the non-European specialist markets
